Breaking News, Collaborations & Alliances

Lonza to Manufacture AstraZeneca’s COVID-19 Long-Acting Antibody Combination

cGMP manufacturing of the two long-acting antibodies to begin in H1 2021 at Lonza's Portsmouth, NH (USA) site.

By: Contract Pharma

Contract Pharma Staff

Lonza has signed an agreement with AstraZeneca to manufacture AZD7442, a combination of two long-acting antibodies (LAABs) for the potential prevention and treatment of COVID-19. AZD7442 is currently in Phase I clinical studies and AstraZeneca plans to advance the LAAB combination into Phase 3 trials in the coming weeks.   The agreement enables AstraZeneca to leverage Lonza’s extensive antibody manufacturing expertise, as well as QC testing, regulatory competence, and experience with acc...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters